The physiological role of the Raf-1 kinase, the cellular homologue of the v-raf oncogene, has been a subject of intensive investigations in recent years. A wide variety of growth factors and cytokines lead to the activation of Raf-1 in many different cell types (reviewed in refs [1] [2] [3] . The molecular mechanism of Raf-1 activation is complex and still incompletely understood, but in many situations involves the small G-protein Ras. In its GTP-loaded state, Ras binds to Raf-1 with high affinity (reviewed in refs 4, 5) resulting in the translocation of Raf-1 to the plasma membrane (6, 7) , where Raf-1 becomes activated by a still unknown mechanism, which involves phosphorylation on tyrosine and/or serine residues (reviewed in ref 8) . Activation may be further enhanced by a lipid cofactor (9) .
Activated Raf-1 phosphorylates and activates MEK (10 -12) , a dual specificity kinase that in turn phosphorylates and activates MAPK/ERK, which propagates the signal to nuclear transcription factors, most notably the ternary complex factor, which is required for the transcription of the c-fos gene (13, 14) . As constitutively activated MEK mutants can transform NIH 3T3 cells and induce differentiation of PC12 cells, thereby mimicking the effects of v-raf, it has been suggested that activation of the MEK/ ERK cascade is the main, if not sole, biological function of Raf-1 (15) . Several lines of evidence indicate, however, that Raf-1 may signal independently of the MEK/ERK pathway. First, v-raf can transform Rat fibroblasts without activation of ERKs (16, 17) . Second, Ras mutants have been isolated that still bind Raf-1 and consequently lead to ERK activation, but fail to induce DNA synthesis or transformation (18, 19) . Third, oncogenic Raf-1 can induce the differentiation of 3T3L1 cells into adipocytes without activating ERKs (20, 21) . Collectively, these findings suggest the existence of other effectors and substrates of Raf-1.
Therefore, we set out to identify new Raf-1 signaling pathways and discovered that Raf-1 associates with vimentin and vimentin kinases that regulate the architecture of vimentin filaments. Vimentin is the main constituent of intermediate filaments in mesenchymal cells. Vimentin filaments are dynamic structures that are constantly being rebuilt by an ongoing exchange of vimentin protomers between the soluble and polymeric phases (reviewed in refs 22, 23) . Although the exact function of the vimentin skeleton is still unknown, it is clear that its architecture is regulated in response to many extracellular stimuli and during the cell cycle. In part this regulation is exerted through phosphorylation, and vimentin has been described as a target for several kinases (reviewed in ref 24 ). Here we show that Raf-1 can signal vimentin rearrangements via the regulation of associated vimentin kinases that are independent of the MEK/ERK pathway.
MATERIALS AND METHODS

Cell lines and reagents
HF-5, NIH 3T3, and COS-1 cells were maintained in Dulbecco's minimal essential medium (DMEM, Serva, Heidelberg, Germany) supplemented with glutamine and 10% fetal calf serum (FCS) from Seromed (Berlin, Germany) or Life Technologies, Inc./BRL (Grand Island, N.Y.). The generation and maintenance of BXB-ER cells were described previously (25) . The MEK inhibitors PD098059 and U0126 were purchased from New England Biolabs (Beverly, Mass.) and Promega (Madison, Wis.), respectively.
Isolation and identification of vimentin
3 ϫ 10 9 logarithmically growing NIH 3T3 cells were lysed in TBS-1% Triton (TBST: 20 mM TrisHCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% Triton-X100, 1 mM PMSF, 10 M leupeptin). The lysate was cleared by centrifugation at 21,000 g for 10 min and incubated with glutathione Sepharose beads (Pharmacia, Piscataway, N.J.) for 1 h at 4°C. The beads were loaded with ϳ5 g of GST or GST-Raf-1 proteins that were expressed in the baculovirus/Sf-9 cell system and purified as described (26) . Beads were washed with TBST five times before GST-Raf-1 and associated proteins were released with sodium dodecyl sulfate (SDS) gel sample buffer (3% SDS, 10 mM DTT, 20 mM TrisHCl, pH 6.8), separated on a 10% SDS gel, and blotted onto nitrocellulose. The blot was stained with Ponceau S. Proteins were cut out from the blot and digested with sequencing grade trypsin (Boehringer Mannheim, Mannheim, Germany) (27) . Tryptic peptides were dissolved in 60 l of 0.1% trifluoroacetic acid and separated on an Aquapore 300 Angström C8 column (1ϫ30 mm) using an Applied Biosystems Model 172 Microbore high-performance liquid chromatography (HPLC). Peptide peaks were microsequenced in a Model 477A gas phase sequenator (Applied Biosystems, Foster City, Calif.).
Vimentin phosphorylation and polymerization assays
Vimentin was expressed in Escherichia coli and purified as described (28) . Vimentin preparations in 8M urea were dialyzed against 10 mM TrisHCl, pH 7.4, 1 mM DTT, and 1 mM EDTA. Insoluble material was removed by centrifugation at 21,000 g for 20 min. The supernatant containing soluble vimentin protomers was incubated with purified GST-Raf-1 proteins bound to glutathione Sepharose in a low-salt Raf-1 kinase buffer (20 mM TrisHCl, pH 7.4, 20 mM NaCl, 10 mM MgCl 2 ) supplemented with 2 M ATP and 2.5 Ci of [
32 P]-␥-ATP. In the course of experimentation, we discovered that low urea concentrations do not affect Raf-1 kinase activity and yielded identical results. Therefore, urea-containing vimentin preparations were used in the kinase assays shown in Fig. 3 . GST-Raf proteins were produced in Sf-9 cells, activated, and purified as described (26) . The protein kinase C␣ (PKC␣) -activated Raf preparations were devoid of detectable contamination by PKC␣. Inclusion of a specific PKC inhibitor (1 M GF203109X, Biomol, Plymouth Meeting, Pa.) did not alter Raf-1 mediated vimentin phosphorylation. Kinase reactions were carried out as described previously (26) . After the phosphorylation reaction, vimentin polymerization was induced by addition of NaCl to a final concentration of 150 mM and allowed to proceed for 30 min at room temperature. Vimentin polymers were pelleted by centrifugation at 21,000 g for 20 min (28) . The pellet was washed twice by vigorous resuspension in TBST before boiling in SDS gel sample buffer. Samples were separated by SDS-gel electrophoresis and blotted onto nitrocellulose membranes. The blots were autoradiographed and subsequently stained with vimentin or Raf antisera as indicated. Soluble activated Raf-1 was produced as follows. GST-Raf-1 was activated by coexpression of Ras plus Lck in Sf-9 cells. After purification the Raf-1 portion was released from the glutathione Sepharose beads by digestion with 0.5 g thrombin. Thrombin was inactivated by addition of 10 g/ml leupeptin.
Phosphopeptide mapping
To assay vimentin phosphorylation in vivo, COS-1 cells were transfected with a v-raf expression plasmid (29) . For transfection, 20 -40% confluent COS-1 cells were incubated in 6-well plates (Nunc, Roskilde, Denmark) containing 2 ml DMEM with glutamine and 10% NU-serum (Collaborative Research, #55000) per well; 5 g of 3611-v-raf plasmid DNA and 20 l DC-mix (10.3 mg/ml chloroquin phosphate, Sigma, and 80 mg/ml DEAE-dextrane, Sigma D-9885) were added to each well. After 4 h the medium was replaced by phosphatebuffered saline (PBS) containing 10% DMSO for 2 min. Then cells were fed with DMEM plus 10% FCS. Two days after transfection, cells were incubated in serum-free medium overnight before harvest. Two days after transfection, COS-1 cells were serum starved overnight, followed by additional incubation in phosphate-free medium (Sigma, St. Louis, Mo.) for 3 h. Then cells were metabolically labeled by addition of 0.5 mCi/ml [ 32 P]-orthophosphoric acid for 3 h. Cells were lysed and vimentin was extracted as described (30) . In parallel, purified vimentin was phosphorylated by Raf-1 in vitro. Samples were resolved by SDS-gel electrophoresis. Vimentin bands were cut out and digested with sequencing grade trypsin (Promega) according to the instructions provided by the manufacturer. Tryptic phosphopeptides were processed for 2-dimensional peptide mapping as described (26) and spotted onto 20 ϫ 20 cm phosphocellulose plates (Merck, Rahway, N.J.). In the first dimension, peptides were resolved by electrophoresis in pH 8.9 buffer at 1250 volts for 15 min; the second dimension was chromatography in nbutanol/pyridine/acetic acid/water (15/10/3/12) for 20 h.
Immunoprecipitation and Western blotting
Approximately 1 ϫ 10 7 growing NIH 3T3 cells were lysed in TBST buffer. To increase the yield of soluble vimentin, NaCl was omitted from the lysis buffer in some experiments. Lysates were cleared by centrifugation at 21,000 g for 10 min and immunoprecipitated with crafVI antiserum (1.5 l per ml of lysate) or the corresponding preimmune serum. The crafVI serum was raised by immunizing rabbits with a peptide corresponding to the unique carboxy-terminal 12 amino acids of Raf-1 (26) . Immunoprecipitates were washed four times with TBST, then resolved by electrophoresis on 7.5% SDS gels and transferred to nitrocellulose membranes. Blots were stained with anti-vimentin antibody (Vim3B4, Boehringer) using the enhanced chemiluminescence kit (Amersham, Arlington Heights, Ill.) as described previously (26) . The antibodies were removed by incubating the membrane in 3% SDS and 10 mM DTT for 15 min. Subsequently, Raf-1 was detected by staining with the PBB1 monoclonal Raf antibody (31) . Soluble vimentin was precipitated with the V9 (DAKO, Carpinteria, Calif.) monoclonal antibody and Raf-1 was detected by staining with PBB1.
Cell fractionation
For the experiment shown in Fig. 8d , 1 ϫ 10 6 COS-1 cells were transfected with GST-BXB and MEK-DD (32) expression plasmids using Superfect (Qiagen, Chatsworth, Calif.) according to the manufacturer's instructions. Two days after transfection, the cells were treated with 50 M U0126 (Promega) for 8 h and then lysed in 400 l TBST. The lysates were separated into soluble and insoluble fractions by centrifugation at 20,000 g for 30 min. The insoluble pellet was sonicated and boiled in 400 l SDS-gel sample buffer. Blots were sequentially stained with antibodies against vimentin (V9, DAKO), phospho-ERK (Sigma) and pan-ERK (Sigma). For the experiment shown in Fig. 8c, 1 ϫ 10 7 BXB-ER cells were labeled with 0.5 mCi/ml [ 32 P]-orthophosphoric acid for 3 h before cells were treated with 1 M estradiol (Sigma) as indicated. Lysates were prepared as above and vimentin was immunoprecipitated from the soluble fraction with the V9 (DAKO) antibody.
In vitro vimentin binding experiments
For the experiments shown in Figs. 2d, e, ϳ1 ϫ 10 8 logarithmically growing NIH 3T3 cells were lysed in 12 ml of 20 mM TrisHCl, pH 7.5, 0.1 mM EDTA, 1% Triton X-100 plus phosphatase, and protease inhibitors. Lysates were cleared by centrifugation at 20,000 g for 5 min and the supernatants were incubated with the indicated GST-Raf proteins immobilized on glutathione agarose beads (Pharmacia) for 12 h at 4°C. Beads were washed in lysis buffer four times, separated on 12.5% SDS-gels, and sequentially immunoblotted with antibodies to vimentin (V9, DAKO; and goat anti-vimentin polyclonal antibody, Sigma) and GST (Santa Cruz, Santa Cruz, Calif.). GST, GRS, GNX, and GST-Raf proteins were expressed in Sf-9 insect cells and purified as described (26) . For the experiments shown in Fig. 2e , the GST-tagged Raf-1 kinase domain GNX was expressed in E. coli. The GNX mutants were generated by progressive deletions from the carboxyl terminus and are described in (33) . For the experiments shown in Fig. 2g , NIH cells were serum starved overnight and stimulated with TPA (100 ng/ml) as indicated. Synthetic peptides were coupled to a chromatographic matrix using the Ultralink kit (Pierce, Rockford, Ill.). The sequence of the 259 peptide is QRQRSTS 259 TPNVHC, the sequence of the 621 peptide is KINRSAS 621 EPSLHRC. Corresponding phosphopeptides were synthesized with phosphoserine at positions 259 and 621, respectively. Incubation with cell lysates was done as described above, but only for 2 h. Associated proteins were cut out from Coomassie-stained gels, digested with trypsin, and identified via mass determination of tryptic peptides by mass spectrometry on a Bruker MALDI-TOF. MASCOT (www.matrixscience.com) was used for databases queries.
Immunofluorescence
For immunofluorescence experiments, human HF-5 or mouse NIH 3T3 fibroblasts were grown on chamber slides (Nunc), washed with PBS, and fixed in methanol for 10 min at Ϫ20°C. Samples were blocked with 10% serum in PBS for 30 min and incubated with primary antibodies diluted in PBS plus 10% serum for 2 h at room temperature or for 16 h at 4°C. FITC-coupled anti-mouse immunoglobulin G (IgG) (Jackson Laboratories, West Grove, Pa.) was used to detect anti-vimentin monoclonal antibodies and TRITC-coupled anti-rabbit IgG was used to visualize Raf-1. Between and after incubations the slides were washed four times with PBS plus 0.25% Triton X-100. The crafVI antiserum was used at a 1:100 dilution or 1:1000 after affinity purification with the corresponding peptide, respectively. To ascertain antibody specificity, the following control experiments were performed. When slides were incubated with mismatched combinations of primary and secondary antibodies, i.e., crafVI (rabbit) and FITC-coupled anti-mouse IgG, or anti-vimentin (mouse) with TRITC-coupled anti-rabbit IgG, no staining was observed. Preincubation of the crafVI serum with the same volume of the peptide antigen (10 mg/ml) used for immunization abolished the Raf stain. To assure the specificity of the vimentin stain, three different monoclonal vimentin antibodies were used including 7A3 (34), clone Vim3B4 (Boehringer) and clone 65E (Affinity, Neshanic Station, N.J.). All antibodies used individually or as mixture gave indistinguishable results. Photographs were taken at 1000ϫ magnification through a Zeiss Axiovert epifluorescence microscope. To exclude 'bleed through' artifacts during photography, slides stained with crafVI or vimentin antibodies alone were included as controls.
RESULTS
Isolation of vimentin as Raf-1-associated protein
Raf-1 associates with its substrate MEK quite stably (35, 36) . Therefore, we tried to exploit this property to identify new Raf-1 substrates by isolating Raf-1-associated proteins. For this purpose, glutathione-Stransferase (GST) -tagged Raf-1 was expressed in the baculovirus/Sf9 cell system and purified by adsorption to glutathione-Sepharose beads. Subsequently, immobilized GST-Raf-1 and a control protein (GST) were incubated with NIH 3T3 lysates. After washes with TBS-1% Triton, the GST-Raf-1 beads were eluted with SDS, separated by SDS-polyacrylamide gel electrophoresis (PAGE), and blotted. Several bands were found to specifically associate with Raf-1, but not with GST (Fig. 1a) . The most abundant band migrated at 58 kDa. It was cut out from the blot, digested with trypsin, and the tryptic peptides were separated by reversed phase HPLC. Two of the collected fractions that appeared to contain only a single peptide were analyzed by microsequencing. The sequence of both tryptic peptides exhibited 100% homology with mouse vimentin (Fig. 1b) .
Interaction between Raf-1 and vimentin
To test whether Raf-1 and vimentin are associated in cells, NIH 3T3 lysates were immunoprecipitated with anti-Raf-1 (crafVI) or the corresponding preimmune serum. The Immunoprecipitates were resolved by SDS-PAGE, blotted, and stained with a monoclonal anti-vimentin antibody. Subsequently, the blot was stripped and stained with Raf-1 specific antiserum ( Fig. 2a) . As evident from Fig. 2a , vimentin was found in the Raf-1 immunoprecipitate. Due to its similar size, vimentin comigrated with the immunoglobulin heavy chains, which somewhat distorted the vimentin band. Therefore, the specificity of the vimentin stain was confirmed by using several different anti-vimentin antibodies (data not shown). In the reciprocal experiment, Raf-1 was coimmunoprecipitated by anti-vimentin antibodies but not control immunoglobulins.
The Raf-1 association with vimentin in intact cells was further corroborated by immunofluorescence experiments in human and mouse fibroblasts, where cells were simultaneously stained with anti-raf-1 and anti-vimentin antibodies (Fig. 2b, c) . The specificity of the antibodies was assured as described in Materials and Methods. Vimentin forms a filamentous reticular network throughout the cytoplasm. Raf-1 was diffusely distributed in the cytosol, but also detected in fibrillar structures that showed extensive overlap with vimentin filaments. The spread-out morphology and larger size of HF-5 facilitated visualization of the colocalization (Fig. 2b) , but consistent findings were obtained in NIH 3T3 cells (Fig.  2c ) and after nocodazole treatment of NIH 3T3 and HF-5. Nocodazole disrupts the ordered architecture of intermediate filaments, resulting in a cotton balllike appearance of vimentin filaments, which also colocalized with Raf-1 (data not shown). These data indicate that Raf-1 can bind to vimentin in intact cells and colocalizes with the vimentin scaffold.
However, in vitro experiments using highly purified vimentin and Raf-1 proteins produced in E. coli or insect cells failed to reveal interactions (data not shown), suggesting that the interaction between Raf-1 and vimentin was indirect and mediated by a yet unknown component. Since vimentin binding to Raf-1 was readily observed in crude cell lysates, we used NIH 3T3 cell lysates to map the vimentin binding domains in Raf-1. Although vimentin bound to both the regulatory and catalytic portions of Raf-1, the main binding domain appeared to be located in the kinase domain (Fig. 2d) . To refine the binding site in the Raf kinase domain, we used deletion mutants (Fig. 2e, f ) . Vimentin binding was severely reduced by the deletion of 28 carboxyl-terminal Raf-1 amino acids and virtually eliminated by further deletion, indicating that the predominant vimentin binding domain resides in the extreme carboxyl terminus of Raf-1. The existence of at least two vimentin binding sites in Raf-1 was serendipitously and independently confirmed in the course of experiments where we used small peptide domains as affinity baits to isolate the protein components of b) The Raf-1-associated 58 kDa band was cut out from the blot and digested with trypsin. Tryptic peptides were separated by reversed phase HPLC and individual peaks were microsequenced. Complete sequence data could be obtained from two tryptic peptides that showed 100% homology to murine vimentin. They appear in boldface and underlined in the mouse vimentin sequence.
Raf-1 signaling complexes. In these experiments vimentin was identified as a protein that binding to peptides encompassing two major Raf-1 phosphorylation sites, serine 259 and 621, respectively (Fig. 2g) . Although the phosphorylation of either residue did not affect vimentin binding, binding was detected only when lysates from stimulated cells were used. The specificity of these associations was further evidenced by the failure of vimentin to bind to any other of 5 small Raf domains used in the same experiment. The binding to the serine 621 peptide is fully consistent with the mapping data derived from the Raf kinase deletion mutants (Fig. 2e, f ) , which show that the removal of amino acids 621-649 (GNX⌬28) compromises vimentin binding.
Phosphorylation of vimentin
Since vimentin is a phosphoprotein (22), we examined whether it is a substrate for the Raf-1 kinase. Purified activated GST-Raf-1 produced in Sf-9 cells was washed either with TBST or RIPA buffer. In contrast to TBST, washes with RIPA remove 14 -3-3, casein kinase 2 (CK2), and other Raf-1-associated proteins (37, 38) . These Raf-1 proteins were tested for phosphorylation of purified, solubilized vimentin and recombinant kinase negative MEK, both produced in E. coli (Fig. 3a) . Since the vimentin preparations used in this experiment contained urea, the effect of an equivalent amount of urea on the kinase activity of Raf-1 was examined as control. Addition of vimentin clearly results in the appearance of a new phosphorylated band. However, the phosphorylation of vimentin by Raf-1 can efficiently be prevented by washing with RIPA buffer, whereas neither the RIPA washes nor the presence of urea significantly diminished MEK phosphorylation by Raf-1.
These results suggested that vimentin phosphorylation did not require Raf-1 kinase activity. To confirm this notion, we repeated this experiment using a kinase negative GST-Raf-1 mutant, Raf-301 (Fig. 3b,  c) . In Raf-301, catalytic activity has been eliminated by replacing lysine 375 with tryptophan (39) . As observed with wild-type Raf-1, the phosphorylation of vimentin by TBST-washed Raf-301 could be completely abolished by washing with RIPA buffer. In contrast, Raf-301 failed to autophosphorylate or phosphorylate MEK under either condition. These results clearly demonstrate that vimentin is phosphorylated by an associated kinase rather than by Raf-1 directly. To exclude that the vimentin kinase(s) associated with the GST portion rather than with Raf-1 itself, we tested whether GST preparations from Sf-9 insect cells could phosphorylate vimentin (Fig. 3b, right panel) . The result clearly demonstrated that vimentin phosphorylation is dependent on Raf-1. To test whether the Raf-1-associated vimentin kinases also are present in mammalian cells, Raf-1 immunoprecipitates prepared from mammalian cell extracts were examined for vimentin phosphorylation (Fig. 3c, right panel) .
We have previously reported that the catalytic ␣ subunit of CK2 associates with Raf-1 (37). To test whether CK2 was responsible for the vimentin kinase activity associated with Raf-1, we used heparin, a CK2 inhibitor (40) . Heparin did not affect MEK phosphorylation by Raf-1 (37) . However, the addition of heparin to TBST washed GST-Raf-1 and GST-Raf301 led to a significant, but not complete reduction of vimentin phosphorylation by both Raf preparations as well as by Raf-1 immunoprecipitates (Fig. 3c) . On the other hand, purified CK2 phosphorylated vimentin (Fig. 4) and was completely inhibited by the same dose of heparin that partially interfered with vimentin phosphorylation by Raf-1. In summary, these experiments suggested that Raf-1 is associated with at least two different vimentin kinases, one of which is likely to be CK2. We found that the activation status of Raf-1 showed a positive correlation with the phosphorylation rate of vimentin (Fig. 5) . Activated and nonactivated GST-Raf and GST-BXB were prepared in Sf-9 cells. GST-Raf-1 was activated by coexpression with Ras plus Lck and GST-BXB by coexpression with PKC␣ (26) . These Raf proteins were immobilized on glutathione Sepharose beads, washed with TBST, and incubated with purified vimentin under Raf kinase conditions. The moderate vimentin phosphorylation that was observed when using unactivated preparations of Raf-1 proteins increased significantly when activated Raf-1 or BXB preparations were used. To exclude that undetected traces of PKC␣ in the Raf preparations were responsible for vimentin phosphorylation, the assays were also performed in the presence of the specific PKC inhibitor GF 109203X, yielding identical results (data not shown). Likewise, Lck did not phosphorylate vimentin in vitro (data not shown). These observations suggest that Raf-1 induces vimentin phosphorylation indirectly via activation of its associated vimentin kinases.
To investigate whether Raf-1 can also stimulate the phosphorylation of vimentin in vivo, COS-1 cells were transiently transfected with v-raf, the constitutively active homologue of Raf-1. v-raf was used in order to selectively display Raf-dependent phosphorylation events and to circumvent the need to activate Raf-1 by mitogen stimulation, which induces many other kinases independent of Raf-1. Transfected cells were serum starved and labeled with [ 32 P]-orthophosphoric acid (Fig. 6) . Vimentin was isolated, digested with trypsin, and the tryptic peptides were resolved on 2-dimensional phosphopeptide maps. In vector-transfected control cells, vimentin exhibited basal phosphorylation of three peptides (labeled 1, 2, and 5). v-raf expression enhanced phosphorylation of the preexisting sites and induced four novel sites. A subset of four phosphopeptides (peptides 1-4) was common to the tryptic phosphopeptide maps of the in vitro and in vivo samples. These results show that vimentin is a downstream target of activated Raf-1 in vivo and in vitro. To confirm that CK2 is one of the Raf-1-associated vimentin kinases and to investigate which phosphorylation sites can be attributed to CK2, we compared phosphopeptide maps of vimentin phosphorylated by GST-Raf-1 (in the absence and presence of heparin) and CK2 in vitro (Fig. 7) . CK2 phosphorylated only one peptide. This corresponded to a prominent phosphopeptide that is phosphorylated by TBST-Raf-1 and eliminated by heparin. Due to the complexity of the phosphopeptide maps, we could not unequivocally identify this peptide in the in vivo map. However, multiple comparisons of several experiments strongly suggest that it corresponds to peptide 1, which is also a major in vivo phosphorylation site.
Raf-1 activation induces the rearrangement of vimentin filaments independent of MEK and ERK
Since Raf-1 induced vimentin phosphorylation in vitro and in vivo, we tested whether Raf activation could impinge on the structure of the vimentin network in cells. We therefore used NIH 3T3 cells, which express BXB-ER, a Raf-1 mutant whose activity can be conditionally regulated by estrogen (25) . In BXB-ER, the Raf-1 kinase domain is fused to the hormone binding domain of the estrogen receptor. The kinase activity of this fusion protein can readily be induced by administration of estrogen, resulting in activation of the MEK/ERK pathway and transformation of the cells (41) . Thus, BXB-ER allows us to study the effects of selective Raf activation independent of the pleiotropic effects caused by growth factors. Serum-starved BXB-ER or NIH 3T3 control cells were treated with estrogen and the vimentin filament network was examined by immunofluorescence (Fig. 8a) . BXB-ER activation induced a rearrangement of vimentin filaments into cable-like bundles and the concomitant dissolution of the reticular scaffold. Bundle formation can be triggered by hyperphosphorylation and is typically connected with the disassembly of the vimentin scaffold, which collapses into tight bundles in the course of being dismantled (30, 42) . These changes, which ensued 2 h after the activation of BXB-ER, were most pronounced between 4 and 8 h and were almost completely reversed after 24 h. This time frame clearly precedes the induction of morphological transformation, which takes at least 24 h to manifest (25) . Thus, the reorganization of the vimentin scaffold was not simply a consequence of cellular transformation. Similar changes in the vimentin skeleton were observed after serum treatment of serum-starved BXB-ER. A quantitative evaluation showed that estrogen and serum induced vimentin rearrangements with similar efficiencies and kinetics (Fig. 8b) . The MEK inhibitor PD98059 did not interfere with BXB-ERinduced vimentin rearrangement (Fig. 8a) , indicating that it was not due to the MEK/ERK pathway but occurred independently. In addition, neither MEK nor MAPK could phosphorylate vimentin in vitro, further confirming that the rearrangement of vimentin in the cell was not mediated by MEK or ERK (data not shown).
To verify that the collapse of vimentin filaments in response to activation of BXB-ER was accompanied by phosphorylation and solubilization, we labeled BXB-ER cells with [ 32 P]-orthophosphoric acid and separated the lysates into detergent-soluble and insoluble fractions (Fig. 8c) . The amount of vimentin that could be immunoprecipitated from the soluble fraction increased dramatically upon BXB-ER activation, whereas insoluble vimentin filaments decreased. Solubilization was connected with phosphorylation as indicated by the preferential incorporation of 32 P label into soluble vimentin. These results suggest that BXB-ER causes vimentin rearrangements by induction of vimentin phosphorylation, which leads to the solubilization of filaments. To further corroborate this hypothesis we transiently transfected COS-1 cells with BXB or an activated MEK-1 mutant, MEK-DD (32), and fractionated the cells as above (Fig. 8d) . BXB led to a pronounced redistribution of vimentin from the insoluble pellet to the soluble phase, whereas MEK-DD was ineffective. The BXB-mediated vimentin solubilization was completely resistant to the MEK inhibitor U0126, although this inhibitor markedly suppressed ERK activation by BXB. In summary, these experiments demonstrate a strong correlation in vivo between Raf activity, vimentin phosphorylation, and vimentin depolymerization, which, however, is independent of MEK and ERK.
The above experiments pointed to a new effector that links Raf-1 to vimentin, but of course could not reveal how many steps downstream of Raf-1 this effector was. The simplest and immediately testable possibility was that the effector(s) was one or more of the Raf-1-associated vimentin kinases. Therefore, we assayed whether phosphorylation by TBST-washed Raf-1 preparations could affect vimentin filaments in vitro. Polymerized vimentin filaments were incubated with activated GST-Raf-1 or purified CK2 under Raf kinase conditions (Fig. 9a) . At different time points, the samples were separated into soluble and insoluble fractions by centrifugation and the distribution of vimentin was examined by Western blotting. Quantitative evaluation of the Western blots by laser scanning densitometry showed that incubation with activated Raf-1 resulted in the progressive redistribution of vimentin into the soluble phase. In contrast, CK2 caused no significant redistribution of vimentin, and thus is unlikely to mediate the effects of Raf-1 to the vimentin scaffold. . Raf-1 induces vimentin phosphorylation and inhibits polymerization. a) Polymerized vimentin filaments were incubated with soluble activated Raf-1 (Raf-1*) or recombinant CK2␣ in Raf kinase buffer supplemented with 100 M ATP. In the 'w/o' lane kinases were omitted. At the times indicated, aliquots were withdrawn and separated into soluble and insoluble fractions by centrifugation. The amount of vimentin present in these fractions was detected by Western blotting and quantitated by laser densitometry using a Cybertech Laserscan. Results are shown as the ratio between soluble and insoluble vimentin. b) Soluble vimentin was phosphorylated with GST-Raf-1 ('Raf')or GST-Raf-1 that had been activated by coexpression of PKC␣ in Sf-9 cells (Raf*). After the kinase reaction, the GST-Raf-1 beads were removed by centrifugation. The supernatant was further incubated 30 min at room temperature in the presence of 150 mM NaCl to induce vimentin polymerization. Vimentin polymers were pelleted by centrifugation (28) . The supernatant and pellet fractions were boiled in SDS-sample buffer, separated by SDS-PAGE, and blotted. The blot was autoradiographed and the distribution of vimentin was visualized by immunostaining with anti-vimentin antibody.
Vimentin filaments are dynamic structures that are constantly rebuilt due to the exchange of soluble tetramers with polymerized filaments (22, 24) . The slow kinetics of the reaction further suggested that the Raf-1 induced phosphorylation of vimentin did not disrupt vimentin polymers directly, but rather prohibited the reintegration of phosphorylated soluble vimentin into the filaments. To test this hypothesis, soluble vimentin oligomers were phosphorylated with Raf-1 and activated Raf-1 (Fig. 9b) . Immediately after the kinase reaction, vimentin polymerization was induced by raising the NaCl concentration from 20 to 150 mM. Polymerized vimentin was separated from soluble vimentin by centrifugation. The major fraction of phosphorylated vimentin failed to polymerize and was recovered in the soluble fraction. In contrast, unactivated Raf-1 induced little vimentin phosphorylation and did not appreciably inhibit polymerization. These in vitro results are consistent with the in vivo effects of Raf on vimentin filaments, since increasing the rate of disassembly causes the loss of the reticular structure of the vimentin network and its collapse into tight bundles.
Furthermore, these data suggested that the effects of Raf-1 on vimentin are mediated by a Raf-1-activated and -associated vimentin kinase other than CK2. Several kinases have been described that regulate vimentin by direct phosphorylation. These include PKC␣ (43), cdc2 (44) , and PKA (30, 43, 45) . To examine whether any of these could be the associated vimentin kinases of Raf-1, the pattern of phosphorylation sites in vimentin induced by these kinases were compared with the pattern induced by Raf-1 (data not shown). The phosphopeptide maps showed clearly that the phosphorylation sites in vimentin induced by Raf-1 do not match with the phosphorylation sites in vimentin induced by PKC␣, PKA, and cdc2. Thus, these kinases are unlikely candidates for the Raf-1-associated vimentin kinase(s).
DISCUSSION
In this study we present evidence that the Raf-1 kinase is physically linked to the vimentin scaffold and can alter its structure by phosphorylation. In a biochemical screen for Raf-1-associated proteins, we isolated vimentin as a Raf-1-associated protein from NIH 3T3 cell lysates. Immunofluorescence experiments revealed that a fraction of Raf-1 colocalized with vimentin filaments. This is consistent with the emerging hypothesis that Raf-1 participates in different signaling complexes with distinct subcellular distribution. For instance, Raf-1 targeted to the plasma membrane efficiently activated the MEK/ ERK pathway, resulting in proliferation and sensitization to myc-induced apoptosis (46) , whereas Raf-1 targeted to the mitochondrial membrane failed to stimulate the MEK/ERK cascade but prevented apoptosis by inducing the phosphorylation and inactivation of BAD, a proapoptotic molecule (47) . Thus, it appears that Raf-1 is distributed into different pools within the cell and that the coupling of Raf-1 to substrates may be regulated by subcellular colocalization.
We found that Raf-1 can induce vimentin phosphorylation in vitro and in vivo. This activity is due to at least two different Raf-1-associated kinases rather than to Raf-1 catalytic activity. We could tentatively identify one of these kinases as CK2. The removal of CK2 activity from Raf-1 kinase preparations by RIPA buffer (37) or inhibition with heparin resulted in a significant reduction in the phosphorylation of vimentin. As shown by phosphopeptide mapping, CK2 phosphorylated vimentin only on one peptide in vitro, which is also phosphorylated in vivo. Thus, we have identified a novel vimentin kinase that on the basis of its biochemical behavior most likely corresponds to CK2. Inhibition of CK2 diminished, but it did not abolish vimentin phosphorylation by TBSTRaf-1 in vitro. As revealed by phosphopeptide mapping, TBST-Raf-1 induced vimentin phosphorylation on multiple sites, some of which were also induced in v-raf-transfected cells. Therefore, we conclude that Raf-1 associates with at least one other vimentin kinase besides CK2. We tried to identify the other kinase(s) by comparing the phosphorylation site pattern induced by TBST-Raf-1 with the sites phosphorylated by known vimentin kinases. Several kinases have been reported to phosphorylate vimentin in vitro including cdc2 (44) , mos (48) , PKC (43), cAMP dependent kinase, PKA (30, 43, 45) , cGMP dependent kinase (49) , and calmodulin-regulated kinase II (50) . Since the roles of PKA, PKC, and cdc2 in vimentin phosphorylation are much better characterized than those of other kinases, we focused on these three. However, a comparison of the phosphopeptide maps suggests that we can exclude PKC␣, PKA, and cdc2 as Raf-1-associated vimentin kinases, especially since we also were unable to detect coprecipitation or in vitro association (data not shown).
Vimentin phosphorylation by TBST-Raf-1 was dependent on its activation, suggesting that Raf-1 can activate one or more of its associated vimentin kinases. Indeed, we observed that Raf-1 was able to enhance the activity of recombinant CK2␣ in vitro. This activation increased with the amount of Raf-1 added, but was independent of phosphorylation by Raf-1 (data not shown). An activation of CK2 by Raf-1 is also suggested by the observation that v-Raf expression enhanced the phosphorylation of vimentin on a peptide that is phosphorylated by CK2 in vitro. Since v-raf expression also enhanced vimentin phosphorylation on other sites, we believe that Raf-1 can also activate vimentin kinases in cells.
These kinases seem to regulate the architecture of vimentin filaments. The activation of a conditional Raf-1 kinase, BXB-ER, in fibroblasts induces the rearrangement of the vimentin scaffold. This was not a consequence of morphological transformation, which ensues hours later and is not caused by changes in the actin cytoskeleton to which vimentin is linked, because BXB-ER does not induce actin rearrangement (25) . In this study, a bundling of microtubules was observed in response to BXB-ER activation that slightly resembles the bundling of vimentin filaments seen here. The effect on the microtubules, however, was mediated via the MEK/ ERK pathway and could be blocked by MEK inhibition (25) . In contrast, vimentin rearrangement in response to BXB-ER activation is not affected by MEK inhibition and therefore occurs independently of microtubule rearrangement. Our in vitro experiments indicate that this effect is due to Raf-1-associated kinases that phosphorylate vimentin and thereby interfere with polymerization. Due to the complex phosphorylation pattern, we have not been able to determine which phosphorylation sites are responsible. CK2 phosphorylation does not seem to play a role, since it fails to affect vimentin filaments in vitro.
In the cell, vimentin filaments are not static structures but are continuously rebuilt due to the incorporation of soluble vimentin tetramers into the polymers. This exchange seems to be important for maintaining the structure of the vimentin cytoskeleton. The assembly and higher order arrangement are altered in response to cell cycle or differentiation specific cues (22) . These processes are regulated at least partly by vimentin phosphorylation (22, 51, 52) . Only the role of the cell cycle-regulated cdc-2 kinase in the disassembly of vimentin filaments during mitosis is well established (44, (53) (54) (55) . Mitosis is accompanied by an increase in vimentin phosphorylation. Depending on the cell type, the vimentin scaffold undergoes a major rearrangement or complete disintegration during mitosis (44) . These differences may be due to variations in the stoichiometry of vimentin phosphorylation by cdc-2 or could reflect the cell type-specific participation of other vimentin kinases (44) . Consistent with the latter hypothesis, PKC (56) and v-mos (57) have been reported as mitotic vimentin kinases.
The physiological meaning of vimentin phosphorylation during interphase is less clear and may also be cell type dependent (22, 58) . This uncertainty stems primarily from the incomplete knowledge about the precise functions of intermediate filaments. Evidence suggests that intermediate filaments do not just serve "as mechanical integrators of cellular space" (59), but may also be involved in regulatory processes such as transformation (60) , differentiation (61) (62) (63) (64) , cellular senescence (65), secretion (66) , and even control of gene expression (67) . Given the diverse functions of intermediate filaments, however, it appears plausible that their structural organization is adapted to specific cellular requirements by regulatory mechanisms, which conceivably could involve different kinases. Under in vitro conditions, vimentin filaments can be disrupted by PKC or cAMP-dependent kinase (PKA) -mediated phosphorylation (68, 69) of vimentin on sites other than cdc-2 (44) . Microinjection of the catalytic subunit of PKA into rat embryo fibroblasts caused the disassembly and collapse of vimentin filaments into tight bundles (30) , and stimulation of Swiss 3T3 cells with cAMP agonists resulted in a similar redistribution of vimentin filaments (70) . Unlike many other cell lines, including NIH 3T3, cAMP acts as a growthpromoting factor in Swiss 3T3 cells, suggesting that vimentin rearrangement may be part of the mitogenic response. This idea is supported by our observation that in NIH 3T3 cells stimulation with serum growth factors as well as the selective activation of BXB-ER by estrogen both trigger vimentin bundling with similar kinetics.
Taken together, our data demonstrate that activation of the Raf-1 kinase induces extensive vimentin reorganization similar to that seen during growth factor stimulation. Whether the changes of the vimentin scaffold are required for the execution of the mitogenic response has to await future studies. The important finding of our study, however, is the identification of a novel branch point in Raf-1 signaling that links Raf-1 with the cytoskeleton via associated vimentin kinases.
